What Is Jelmyto and What Does It Treat?
Jelmyto is a sterile gel formulation of mitomycin, approved by the FDA for treating low-grade upper tract urothelial carcinoma (LG-UTUC)—a cancer affecting the lining of the kidney's renal pelvis and ureter, not the kidney tissue itself.[1] It's instilled directly into the renal pelvis or ureter via catheter during a procedure called retrograde endoscopic delivery, where it solidifies at body temperature to release the drug locally before being irrigated out.[1]
How Does Jelmyto Differ from Kidney Cancer Treatments?
Kidney cancer typically refers to renal cell carcinoma (RCC), which arises in the kidney's parenchyma and is treated with surgery (e.g., nephrectomy), targeted therapies like sunitinib, or immunotherapies like nivolumab—not gels like Jelmyto.[2] Jelmyto targets urothelial cancers in the upper urinary tract, which can involve the kidney's collecting system but represent only about 5-10% of urothelial carcinomas, distinct from RCC.[1][3]
When Is Jelmyto Used Instead of Surgery?
Jelmyto is indicated for adults with LG-UTUC who need kidney-sparing treatment, avoiding nephroureterectomy (kidney and ureter removal).[1] Clinical trials showed 1-year complete response rates of 58-77% in low-grade cases, with ablation-free renal survival at about 80% at 12 months.[1] It's not for high-grade tumors or RCC.
What Are Common Side Effects and Risks?
Patients report ureteric obstruction (up to 48%), hematuria (26%), and flank pain (19%), often resolving with irrigation.[1] Ureteral stricture occurs in 10-15% long-term. It's contraindicated in patients unable to tolerate endoscopic procedures or with perforations.[1]
Who Makes Jelmyto and What's Its Patent Status?
Jelmyto (mitomycin for pyelocalyceal solution) is made by UroGen Pharma. Its key patents cover the formulation and delivery method, with U.S. Patent No. 10,709,729 expiring around 2033; check DrugPatentWatch.com for challenges or extensions.[4]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/033985s000lbl.pdf
[2] NCCN Guidelines: Kidney Cancer (2023)
[3] EAU Guidelines: Upper Urinary Tract Urothelial Carcinoma (2023)
[4] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/JELMYTO